Side effects of valproic acid: Daytime incontinence and nocturnal enuresis
Gazzetta Medica Italiana Archivio per le Scienze Mediche, cilt.180, sa.10, ss.557-561, 2021 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 180 Sayı: 10
- Basım Tarihi: 2021
- Doi Numarası: 10.23736/s0393-3660.20.04536-2
- Dergi Adı: Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE
- Sayfa Sayıları: ss.557-561
- Anahtar Kelimeler: Valproic acid, Urinary incontinence, Enuresis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
BACKGROUND: Valproic acid is one of the most common antiepileptic drugs administered for epilepsy in children. It has a lot of adverse effects, and nocturnal enuresis is one of them. An association between the incontinence/nocturnal enuresis and valproate is not well defined in the literature. We aimed to investigate the results of uroflowmetry in VPA administered children who had nocturnal and/or diurnal incontinence. METHODS: Twenty-one patients were included in the study who were followed up with the diagnosis of epilepsy and who had nocturnal enuresis and/or nocturnal enuresis and daytime incontinence with increased micturition after the initiation of VPA. Incontinence symptoms scores and results of uroflowmetry were recorded for each patient as well as detailed physical examination, laboratory and radiologic investigations RESULTS: After the initiation of VPA; 16 patients had only enuresis, five patients had enuresis and day-time incontinence with increased frequency of micturition. Except for one patient with staccato pattern, uroflowmetry results were normal in all 20 patients. No significant difference was found between patients who had only nocturnal incontinence and those who had both nocturnal and daytime incontinence in terms of uroflowmetry results. CONCLUSIONS: Enuresis and daytime incontinence are a distressful problem both for children and parents, so families should be questioned about the presence of enuresis and/or day-time incontinence before the initiation of the VPAtreatment.